Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-19T11:50:00.286Z Has data issue: false hasContentIssue false

34 - Fabry disease

Published online by Cambridge University Press:  31 July 2009

E. Steve Roach
Affiliation:
Department of Neurology, Wake Forest University School of Medicine, Winston–Salem, NC, USA
E. Steve Roach
Affiliation:
Wake Forest University, North Carolina
Van S. Miller
Affiliation:
University of Texas Southwestern Medical Center, Dallas
Get access

Summary

Fabry disease (Anderson–Fabry disease or angiokeratoma corporis diffusum) is an X-linked lysosomal storage disease resulting from deficiency of α-galactosidase A (Brady et al., 1967; Kint, 1970). The first descriptions of the disease date to 1898, when William Anderson and Johannes Fabry independently described some of its clinical features (Fabry, 2001). Fabry disease is completely penetrant in males, who often develop painful paresthesias during childhood and are later at risk for renal failure, heart disease, and stroke. Symptoms in heterozygous females are variable and generally less severe (MacDermot et al., 2001a).

Clinical features

The characteristic skin abnormality of Fabry disease is angiokeratoma corporis diffusum, seen initially as superficial dilated capillaries which keratinize and over time develop a raised dark red or purple appearance (Fig. 34.1). These lesions are widespread, but occur most often in clusters around the umbilicus or on the buttocks, scrotum, hips or thighs (Bethune et al., 1961). The size and number of the cutaneous lesions vary, but they tend to become more numerous with age; a few adults never develop skin lesions (Wallace, 1958; MacDermot et al., 2001b).

Whorled corneal deposits (Fig. 34.2) are characteristic of Fabry disease and occur even in female carriers (Weingeist & Blodi, 1971; Hirano et al., 2001). Some patients also develop anterior capsular deposits and abnormalities of the conjunctival vessels (Sher et al., 1979). Although Fabry disease does not usually cause significant visual loss, these abnormalities may help identify the diagnosis (Sher et al., 1979).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Altarescu, G. M., Goldfarb, L. G., Park, K-Y. et al. (2001). Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clinical Genetics, 60: 46–51CrossRefGoogle ScholarPubMed
Bethune, J. E., Landrigan, P. L. & Chipman, C. D. (1961). Angiokeratoma corporus diffusum (Fabry disease) in two brothers. New England Journal of Medicine, 264: 1280–1285CrossRefGoogle Scholar
Brady, R. O. & Schiffmann, R. (2000). Clinical features of and recent advances in therapy for Fabry disease. Journal of the American Medical Association, 284: 2771–2775CrossRefGoogle ScholarPubMed
Brady, R. O., Gal, A. E., Bradley, R. M., Martensson, E., Warshaw, A. L. & Laster, L. (1967). Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. New England Journal of Medicine, 276: 1163–1167CrossRefGoogle ScholarPubMed
Brown, L. K., Miller, A. & Bhuptani, A. (1997). Pulmonary involvement in Fabry's disease. American Journal of Respiratory and Critical Care Medicine, 155: 1004–1010CrossRefGoogle Scholar
Buhler, F. R., Thiel, G., Dubach, U. C., Enderlin, F., Gloor, F. & Tholen, H. (1973). Kidney transplantation in Fabry's disease. British Medical Journal, 3: 28–29CrossRefGoogle ScholarPubMed
Colucci, W. S., Lorell, B. H., Schoen, F. J., Warhol, M. J. & Grossman, W. (1982). Hypertrophic obstructive cardiomyopathy due to Fabry's disease. New England Journal of Medicine, 307: 926–928CrossRefGoogle ScholarPubMed
Crutchfield, K. E., Patronis, N. J., Dambrosis, J. M., Banerjee, T. K., Barton, N. W. & Schiffmann, R. (1998). Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology, 50: 1746–1749CrossRefGoogle ScholarPubMed
deVeber, G. A., Schwarting, G. A., Kolodny, E. H. & Kowall, N. W. (1992). Fabry disease: immunocytochemical characterization of neuronal involvement. Annals of Neurology, 31: 409–415CrossRefGoogle ScholarPubMed
Eng, C. M., Guffon, N. & Wilcox, W. R. (2001a). Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. New England Journal of Medicine, 345: 9–16CrossRefGoogle Scholar
Eng, C. M., Banikazemi, M. & Gordon, R. E. (2001b). A phase ½clinical trial of enzyme replacement in Fabry disease: pharmacologic, substrate clearance, and safety studies. American Journal of Human Genetics, 68: 711–722CrossRefGoogle Scholar
Fabry, H. (2001). An historical overview of Fabry disease. Journal of Inherited Metabolic Disease, 24: 3–7CrossRefGoogle ScholarPubMed
Ferrans, V. J., Hibbs, R. G. & Burda, C. D. (1969). The heart in Fabry's disease. American Journal of Cardiology, 24: 95–110CrossRefGoogle ScholarPubMed
Friedleander, M. M., Kopolovic, J., Rubinger, D. et al. (1987). Renal biopsy in Fabry's disease eight years after successful renal transplantation. Clinical Nephrology, 27: 206–211Google Scholar
Gangjian, Q., Takenaka, T., Telsch, K. et al. (2001). Preselective gene therapy for Fabry disease. Proceedings of the National Academy of Science, 98: 3428–3433Google Scholar
Grewal, R. P. (1994). Stroke in Fabry's disease. Journal of Neurology, 241: 153–156CrossRefGoogle ScholarPubMed
Hirano, K., Murata, K., Miyagawa, A. et al. (2001). Histopathologic findings of cornea verticillata in a woman heterozygous for Fabry's disease. Cornea, 20: 233–236CrossRefGoogle Scholar
Jung, S-C., Han, I. P., Limaye, A. et al. (2001). Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proceedings of the National Academy of Science, 98: 2676–2681CrossRefGoogle ScholarPubMed
Kahn, P. (1973). Anderson–Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. Journal of Neurology Neurosurgery and Psychiatry, 36: 1053–1062CrossRefGoogle Scholar
Kint, J. A. (1970). Fabry's disease: alpha-galactosidase deficiency. Science, 167: 1268–1269CrossRefGoogle ScholarPubMed
Kleijer, W. J., Hussaarts-Odijk, L. M., Sachs, E. S., Jahoda, M. J. G. & Niermeijer, M. F. (1987). Prenatal diagnosis of Fabry's disease by direct analysis of chorionic villi. Prenatal Diagnosis, 7: 283–287CrossRefGoogle ScholarPubMed
Kocen, R. S. & Thomas, P. K. (1970). Peripheral nerve involvement in Fabry's disease. Archives of Neurology, 22: 81–88CrossRefGoogle ScholarPubMed
MacDermot, K. D., Holmes, A. & Minders, A. H. (2001a). Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. Journal of Inherited Metabolic Disease, 24: 769–775CrossRefGoogle Scholar
MacDermot, K. D., Holmes, A. & Miners, A. H. (2001b). Anderson–Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. Journal of Medical Genetics, 38: 750–760CrossRefGoogle Scholar
Meikle, P. J., Hopwood, J. J., Clague, A. E. & Carey, W. F. (1999). Prevalence of lysosomal storage disorders. Journal of the American Medical Association, 281: 249–254CrossRefGoogle ScholarPubMed
Mitsias, P. & Levine, S. R. (1996). Cerebrovascular complications of Fabry's disease. Annals of Neurology, 40: 8–17CrossRefGoogle ScholarPubMed
Morgan, S. H., Rudge, P. & Smith, S. J. (1990). The neurological manifestations of Anderson–Fabry disease (alpha-galactosidase deficiency): investigation of symptomatic and presymptomatic patients. Quarterly Journal of Medicine, 75: 491–507Google Scholar
Ohnishi, A. & Dyck, P. J. (1974). Loss of small peripheral sensory neurons in Fabry disease. Archives of Neurology, 31: 120–127CrossRefGoogle Scholar
Rowe, J. W., Gilliam, J. I. & Warthin, T. A. (1974). Intestinal manifestions of Fabry disease. Annals of Internal Medicine, 81: 628–631CrossRefGoogle Scholar
Schiffmann, R., Kopp, J. B. & Austin, H. A. (2001). Enzyme replacement therapy in Fabry disease. A randomized controlled trial. Journal of the American Medical Association, 285: 2743–2749CrossRefGoogle ScholarPubMed
Scott, L. J. C., Griffin, J. W., Luciano, C., et al. (1999). Quantitative analysis of epidermal innervation in Fabry disease. Neurology, 52: 1249–1254CrossRefGoogle ScholarPubMed
Sher, N. A., Letson, R. D. & Desnick, R. J. (1979). The ocular manifestations in Fabry's disease. Archives of Ophthalmology, 97: 671–676CrossRefGoogle ScholarPubMed
Siatskas, C. & Medin, J. A. (2001). Gene therapy for Fabry disease. Journal of Inherited Metabolic Disease, 24: 25–41CrossRefGoogle ScholarPubMed
Sirvent, A. E., Enriquez, R., Antolin, A. et al. (1997). Fabry's disease presenting with oligoanuric end-stage renal failure. Nephrology Dialysis Transplantation, 12: 1503–1505CrossRefGoogle ScholarPubMed
Taaffe, A. (1977). Angiokeratoma corporis diffusum: the evolution of a disease entity. Postgraduate Medical Journal, 53: 78–81CrossRefGoogle ScholarPubMed
Topaloglu, A. K., Ashley, G. A. & Tong, B. (1999). Twenty novel mutations in the alpha-galactosidase gene causing Fabry disease. Molecular Medicine, 5: 806–811Google ScholarPubMed
Toyooka, K. & Said, G. (1997). Nerve biopsy findings in hemizygous patients with Fabry's disease. Journal of Neurology, 244: 464–468CrossRefGoogle ScholarPubMed
Scheidt, W., Eng, C. M., Fitzmaurice, T. F. et al. (1991). An atypical variant of Fabry's disease with manifestations confined to the myocardium. New England Journal of Medicine, 324: 395–399CrossRefGoogle Scholar
Wallace, H. J. (1958). Angiokeratoma corporis diffusum. British Journal of Dermatology, 70: 354–360CrossRefGoogle ScholarPubMed
Weingeist, T. A. & Blodi, F. C. (1971). Fabry's disease: ocular findings in a female carrier. Archives of Ophthalmology, 85: 169–176CrossRefGoogle Scholar
Wise, D., Wallace, H. J. & Jellinek, E. H. (1962). Angiokeratoma corporis diffusum: a clinical study of eight affected families. Quarterly Journal of Medicine, 31: 177–205Google ScholarPubMed
Yoshitama, T., Nakao, S., Takenaka, T. et al. (2001). Molecular, genetic, biochemical, and clinical studies in three families with cardiac Fabry's disease. American Journal of Cardiology, 87: 71–75CrossRefGoogle ScholarPubMed
Zeluff, G. W., Caskey, C. T. & Jackson, D. (1978). Heart attack or stroke in a young man? Think Fabry's disease. Heart Lung, 7: 1056–1061Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Fabry disease
    • By E. Steve Roach, Department of Neurology, Wake Forest University School of Medicine, Winston–Salem, NC, USA
  • Edited by E. Steve Roach, Wake Forest University, North Carolina, Van S. Miller, University of Texas Southwestern Medical Center, Dallas
  • Book: Neurocutaneous Disorders
  • Online publication: 31 July 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545054.036
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Fabry disease
    • By E. Steve Roach, Department of Neurology, Wake Forest University School of Medicine, Winston–Salem, NC, USA
  • Edited by E. Steve Roach, Wake Forest University, North Carolina, Van S. Miller, University of Texas Southwestern Medical Center, Dallas
  • Book: Neurocutaneous Disorders
  • Online publication: 31 July 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545054.036
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Fabry disease
    • By E. Steve Roach, Department of Neurology, Wake Forest University School of Medicine, Winston–Salem, NC, USA
  • Edited by E. Steve Roach, Wake Forest University, North Carolina, Van S. Miller, University of Texas Southwestern Medical Center, Dallas
  • Book: Neurocutaneous Disorders
  • Online publication: 31 July 2009
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545054.036
Available formats
×